{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T01:29:51Z","timestamp":1778894991939,"version":"3.51.4"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.anai.2019.06.001","type":"journal-article","created":{"date-parts":[[2019,6,12]],"date-time":"2019-06-12T11:59:02Z","timestamp":1560340742000},"page":"411-412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption"],"prefix":"10.1016","volume":"123","author":[{"given":"Christine R.F.","family":"Rukasin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth J.","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison E.","family":"Norton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.anai.2019.06.001_bib1","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jaip.2018.02.018","article-title":"The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study","volume":"6","author":"Guvenir","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2019.06.001_bib2","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jaip.2018.07.003","article-title":"Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects","volume":"6","author":"Kuyucu","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2019.06.001_bib3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.anai.2019.06.001_bib4","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1111\/epi.13566","article-title":"HLA-B*40: 02 and DRB 1*04: 03 are risk factors for oxcarbazepine-induced maculopapular eruption","volume":"57","author":"Moon","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.anai.2019.06.001_bib5","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A* 3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.06.001_bib6","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.1542\/peds.2017-1361","article-title":"HLA-A*31:01 and oxcarbazepine-induced DRESS in a patient with seizures and complete DCX deletion","volume":"141","author":"Kim","year":"2018","journal-title":"Pediatrics"},{"key":"10.1016\/j.anai.2019.06.001_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/dmcn.13744","article-title":"Phenotypes, genotypes, and the management of paroxysmal movement disorders","volume":"60","author":"Silveira-Moriyama","year":"2018","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.anai.2019.06.001_bib8","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-3083.2011.04418.x","article-title":"A\u00a0patch testing and cross-sensitivity study of carbamazepine-induced severe cutaneous adverse drug reactions","volume":"27","author":"Lin","year":"2013","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.anai.2019.06.001_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pediatrneurol.2014.03.021","article-title":"Human leukocyte antigen genotypes and trial of desensitization in patients with oxcarbazepine-induced skin rash: a pilot study","volume":"51","author":"Lee","year":"2014","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.anai.2019.06.001_bib10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000078583","article-title":"Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization","volume":"209","author":"Teraki","year":"2004","journal-title":"Dermatology"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619304259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619304259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:23:24Z","timestamp":1761053004000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619304259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1081120619304259"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.06.001","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Slow graded reintroduction of oxcarbazepine for delayed maculopapular eruption","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}